AirSculpt Technologies (AIRS) reported a third-quarter loss of $0.10 per share on revenue of $31.94 million. Earnings fell 100.0% year over year and revenue declined 8.7%. No consensus estimate or Earnings Whisper was available, but management did not need one to frame the result: CEO Yogi Jashnani said the quarter came in below expectations. The company cut full-year guidance for the second consecutive quarter. The central takeaway is that the early-2026 recovery narrative has broken down. Same-center demand turned sharply negative, and the business's thin profit cushion nearly disappeared.

The quality of the headline numbers deserves scrutiny because GAAP flatters the comparison. Net loss narrowed to $7.2 million from $9.5 million, but only because the year-ago quarter carried a $7.1 million impairment charge. The adjusted figures show the real trajectory. Adjusted net loss widened to $6.1 million, or $0.08 per share, from $2.4 million, or $0.04. Adjusted EBITDA collapsed to $0.4 million, a 1.2% margin, from $3.0 million (8.7%) a year ago and $4.9 million (11.5%) in the second quarter. Selling, general and administrative expense rose to $20.3 million even as revenue fell, which shows how little operating leverage remains when volume slips. Operating cash flow was negative $3.5 million for the quarter. Shareholders are also absorbing dilution: weighted shares rose to 72.5 million from 62.4 million, and the company raised another $7.2 million through its at-the-market program during the quarter.

Beneath the totals, the problem is demand capture rather than pricing or conversion. Same-center cases fell 9.6% after two quarters of growth. Same-center revenue declined 7.5%, compared with roughly -1% in the second quarter and +1% in the first. Management attributed much of the shortfall to Google AI Overviews reducing search clicks. Leads fell 16% year over year, cost per lead jumped 26%, and customer acquisition cost climbed to about $3,800 per case from $3,500 in Q2 and $3,100 a year ago. Execution issues at a handful of centers compounded the pressure, and some of those problems are taking months to fix. The bright spots are real but secondary. Gross margin improved to about 60% from 57.5% a year ago, though it slipped from roughly 61% in Q2. Average selling price rose 2.3% to about $12,900, and conversion rates held steady. When the funnel shrinks, however, price and conversion cannot offset the lost volume.

The guidance path tells the story of eroding visibility:

• **Revenue:** Now $144-146 million, down from $151-157 million.
• **Adjusted EBITDA:** Now $9-10 million, down from $12-14 million last quarter and $15-17 million at the start of the year.

The new outlook assumes third-quarter weakness persists. It implies fourth-quarter adjusted EBITDA of only around $0.4-1.4 million, and management still described the consumer as choppy. Management also cut planned incremental brand marketing to $3 million from $5 million. That cut protects near-term cash but raises questions about how the company rebuilds lead flow.

The call did preserve some catalysts:

• **GLP-1 procedures:** These have climbed steadily, from more than 100 skin removals in Q4 FY25 to about 250 procedures this quarter, nearly 10% of cases. They are now offered in nearly all centers, and management continues to cite a $100 million-plus long-term opportunity.
• **New initiatives:** The Alloclay rollout is expanding. A first-ever network-wide open house is scheduled for November 12, and the company is shifting toward AI-search optimization and grassroots marketing to reduce its reliance on Google.
• **Refinancing:** The new $39 million term loan and $5 million revolver from Blue Torch push the maturity out to 2031 from November 2027, with lower amortization and more covenant headroom.

The refinancing has a cost. Interest rises roughly 300 basis points to SOFR plus 775, and gross debt edges slightly higher just as EBITDA shrinks. Liquidity has also declined to about $20 million from roughly $24 million in Q2. Bears have legitimate ammunition here: the company has bought time, but at a higher price.

Investor sentiment and current price data were not available for this report. For context, shares opened at $2.87 after the August report, below the current 200-day moving average of $3.10. The stock was already trading at depressed levels before this second guidance cut.

The bottom line is that AirSculpt's third quarter replaced a tentative turnaround story with a customer-acquisition problem that management has not yet shown it can solve. Pricing, gross margin, and GLP-1 procedure growth are holding up, and the refinancing removes a near-term maturity overhang. However, falling same-center volume, rising acquisition costs, near-breakeven EBITDA, and a guidance trajectory that has fallen for two straight quarters leave the burden of proof squarely on execution in the coming quarters.